Johnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the European biotech said there is no guarantee the deal will go through. J&J’s CEO Alex Gorsky said this year that the company is interested in deals […]
Clearside Biomedical names McElheny as biz dev veep | Personnel Moves, Nov. 8, 2016
Clearside Biomedical (NSDQ:CLSD) today named Rick McElheny as its VP of business development. The Alpharetta, Ga.-based company is developing a microinjector loaded with CLS-TA (triamcinolone acetonide) to treat macular edema. The device is designed to inject the compound in the a 30-µm gap between the choroid and the sclera, called the suprachoroidal space. A pivotal Phase III […]
Antibacterial coated suture wins WHO recommendation
Ethicon said today that its triclosan-coated suture was included in the new “Global Guidelines for the Prevention of Surgical Site Infections (SSI)” by the World Health Organization. The guidelines are the 1st global guidelines for preventing surgical site infections. “The panel suggests the use of triclosan-coated sutures for the purpose of reducing the risk of […]
J&J’s Acclarent to pay $18m over off-label marketing charges
Johnson & Johnson (NYSE:JNJ) subsidiary Acclarent will pay $18 million to resolve allegations over false claims submitted to Medicare and other federal health care programs in relation to marketing its Relieva Stratus MicroFlow sinus spacer as a drug-delivery device without FDA clearance. The company won FDA clearance in 2006 to market the Stratus as a […]
Ichor Medical inks $85m drug-device deal with J&J
- « Previous Page
- 1
- …
- 6
- 7
- 8
